Breaking News

Wednesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Pacira price target raised to $62 from $56 at RBC Capital » 06:39
07/01/20
07/01
06:39
07/01/20
06:39
PCRX

Pacira

$52.47 /

+0.44 (+0.85%)

, HRTX

Heron Therapeutics

$14.69 /

+0.435 (+3.05%)

RBC Capital analyst…

RBC Capital analyst Randall Stanicky raised the firm's price target on Pacira (PCRX) to $62 from $56 and keeps an Outperform rating on the shares following his discussion with the management on the latest CRL for Heron Therapeutics' (HRTX) HTX-011. The call addressed Pacira's continued real-time ramp in EXPAREL volumes and growth of revenue drivers, in addition to the company being the "best margins story" in his coverage that will now operate "competition-free" in the short term and possibly beyond, the analyst tells investors in a research note..

ShowHide Related Items >><<
PCRX Pacira
$52.47 /

+0.44 (+0.85%)

HRTX Heron Therapeutics
$14.69 /

+0.435 (+3.05%)

PCRX Pacira
$52.47 /

+0.44 (+0.85%)

06/30/20 SVB Leerink
Pacira price target raised to $58 from $45 at SVB Leerink
06/30/20 SVB Leerink
Heron Therapeutics price target lowered to $19 from $26 at SVB Leerink
06/30/20 Northland
Pacira price target raised to $54 from $50 at Northland
06/29/20 JPMorgan
HTX-011 CRL 'a clear positive' for Pacira, says JPMorgan
HRTX Heron Therapeutics
$14.69 /

+0.435 (+3.05%)

06/30/20 Northland
Northland keeps Outperform on Heron Therapeutics after 'minor setback'
PCRX Pacira
$52.47 /

+0.44 (+0.85%)

HRTX Heron Therapeutics
$14.69 /

+0.435 (+3.05%)

  • 04
    Oct
PCRX Pacira
$52.47 /

+0.44 (+0.85%)

HRTX Heron Therapeutics
$14.69 /

+0.435 (+3.05%)

Tuesday
Recommendations
Pacira price target raised to $58 from $45 at SVB Leerink » 09:17
06/30/20
06/30
09:17
06/30/20
09:17
PCRX

Pacira

$52.03 /

+7.91 (+17.93%)

, HRTX

Heron Therapeutics

$14.26 /

-5.555 (-28.04%)

SVB Leerink analyst Ami…

SVB Leerink analyst Ami Fadia raised the firm's price target on Pacira (PCRX) to $58 from $45 following the latest CRL for Heron Therapeutics' (HRTX) HTX-011. The analyst continues to believe HTX-011 will have a superior profile to Pacira's Exparel, but its "clearly disappointing" to see the approval delayed yet again. Regardless, Fadia sees the development as "a positive" for Pacira, as the delay gives Exparel another year to grow unimpeded, especially over the next few quarters as elective surgeries ramp back up and institutions work through the backlog of procedures. The analyst keeps an Outperform rating on Pacira's shares.

ShowHide Related Items >><<
PCRX Pacira
$52.03 /

+7.91 (+17.93%)

HRTX Heron Therapeutics
$14.26 /

-5.555 (-28.04%)

PCRX Pacira
$52.03 /

+7.91 (+17.93%)

06/30/20 SVB Leerink
Heron Therapeutics price target lowered to $19 from $26 at SVB Leerink
06/30/20 Northland
Pacira price target raised to $54 from $50 at Northland
06/29/20 JPMorgan
HTX-011 CRL 'a clear positive' for Pacira, says JPMorgan
05/27/20 Northland
Pacira downgraded to Market Perform from Outperform at Northland
HRTX Heron Therapeutics
$14.26 /

-5.555 (-28.04%)

06/30/20 Northland
Northland keeps Outperform on Heron Therapeutics after 'minor setback'
06/29/20 Evercore ISI
Heron Therapeutics should be bought on CRL weakness, says Evercore ISI
PCRX Pacira
$52.03 /

+7.91 (+17.93%)

HRTX Heron Therapeutics
$14.26 /

-5.555 (-28.04%)

  • 04
    Oct
PCRX Pacira
$52.03 /

+7.91 (+17.93%)

HRTX Heron Therapeutics
$14.26 /

-5.555 (-28.04%)

Recommendations
Heron Therapeutics price target lowered to $19 from $26 at SVB Leerink » 09:14
06/30/20
06/30
09:14
06/30/20
09:14
HRTX

Heron Therapeutics

$14.26 /

-5.555 (-28.04%)

, PCRX

Pacira

$52.03 /

+7.91 (+17.93%)

SVB Leerink analyst Ami…

SVB Leerink analyst Ami Fadia lowered the firm's price target on Heron Therapeutics (HRTX) to $19 from $26 following the latest CRL for HTX-011. Fadia continues to believe HTX-011 will have a superior profile to Pacira's (PCRX) Exparel, but its "clearly disappointing" to see the approval delayed yet again. The analyst believes Heron will remain in the penalty box until it obtains approval and executes the launch. She keeps an Outperform rating on Heron's shares.

ShowHide Related Items >><<
PCRX Pacira
$52.03 /

+7.91 (+17.93%)

HRTX Heron Therapeutics
$14.26 /

-5.555 (-28.04%)

HRTX Heron Therapeutics
$14.26 /

-5.555 (-28.04%)

06/30/20 Northland
Northland keeps Outperform on Heron Therapeutics after 'minor setback'
06/29/20 JPMorgan
HTX-011 CRL 'a clear positive' for Pacira, says JPMorgan
06/29/20 Evercore ISI
Heron Therapeutics should be bought on CRL weakness, says Evercore ISI
05/27/20 Guggenheim
Guggenheim starts coverage of four pain treatment makers with two Buys
PCRX Pacira
$52.03 /

+7.91 (+17.93%)

06/30/20 Northland
Pacira price target raised to $54 from $50 at Northland
05/27/20 Northland
Pacira downgraded to Market Perform from Outperform at Northland
PCRX Pacira
$52.03 /

+7.91 (+17.93%)

HRTX Heron Therapeutics
$14.26 /

-5.555 (-28.04%)

  • 04
    Oct
HRTX Heron Therapeutics
$14.26 /

-5.555 (-28.04%)

Recommendations
Northland keeps Outperform on Heron Therapeutics after 'minor setback' » 09:03
06/30/20
06/30
09:03
06/30/20
09:03
HRTX

Heron Therapeutics

$14.26 /

-5.555 (-28.04%)

Northland analyst Carl…

Northland analyst Carl Byrnes lowered the firm's price target on Heron Therapeutics to $35 from $47 and keeps an Outperform rating on the shares. The analyst views the Complete Response Letter for HTX-011 as a "minor setback" and remains confident that the pain drug will garner approval. Heron's current valuation is supported by its Cinvanti franchise, with HTX-011 "providing for significant upside," Byrnes tells investors in a research note.

ShowHide Related Items >><<
HRTX Heron Therapeutics
$14.26 /

-5.555 (-28.04%)

HRTX Heron Therapeutics
$14.26 /

-5.555 (-28.04%)

06/29/20 JPMorgan
HTX-011 CRL 'a clear positive' for Pacira, says JPMorgan
06/29/20 Evercore ISI
Heron Therapeutics should be bought on CRL weakness, says Evercore ISI
05/27/20 Guggenheim
Guggenheim starts coverage of four pain treatment makers with two Buys
05/26/20 Guggenheim
Heron Therapeutics initiated with a Buy at Guggenheim
HRTX Heron Therapeutics
$14.26 /

-5.555 (-28.04%)

  • 04
    Oct
HRTX Heron Therapeutics
$14.26 /

-5.555 (-28.04%)

Monday
On The Fly
Fly Intel: Wall Street's top stories for Monday » 16:38
06/29/20
06/29
16:38
06/29/20
16:38
BA

Boeing

$194.42 /

+24.51 (+14.43%)

, SBUX

Starbucks

$73.50 /

+1.95 (+2.73%)

, KO

Coca-Cola

$44.35 /

+0.77 (+1.77%)

, F

Ford

$6.02 /

+0.11 (+1.86%)

, ADDYY

Adidas

$0.00 /

+ (+0.00%)

, FB

Facebook

$220.70 /

+4.84 (+2.24%)

, MSFT

Microsoft

$198.49 /

+2.24 (+1.14%)

, BBY

Best Buy

$86.31 /

+1.58 (+1.86%)

, GILD

Gilead

$74.56 /

+0.04 (+0.05%)

, ICPT

Intercept

$46.66 /

-30.9 (-39.84%)

, HRTX

Heron Therapeutics

$14.26 /

-5.555 (-28.04%)

, AMZN

Amazon.com

$2,682.00 /

-11.16 (-0.41%)

, AMC

AMC Entertainment

$4.43 /

+0.27 (+6.49%)

, IDEX

Ideanomics

$2.06 /

+0.61 (+42.07%)

, KNSA

Kiniksa

$26.00 /

+2.96 (+12.85%)

, BYND

Beyond Meat

$131.52 /

-10.16 (-7.17%)

Stocks saw a rebound from…

Open Full Text

ShowHide Related Items >><<
SBUX Starbucks
$73.50 /

+1.95 (+2.73%)

MSFT Microsoft
$198.49 /

+2.24 (+1.14%)

KO Coca-Cola
$44.35 /

+0.77 (+1.77%)

KNSA Kiniksa
$26.00 /

+2.96 (+12.85%)

IDEX Ideanomics
$2.06 /

+0.61 (+42.07%)

ICPT Intercept
$46.66 /

-30.9 (-39.84%)

HRTX Heron Therapeutics
$14.26 /

-5.555 (-28.04%)

GILD Gilead
$74.56 /

+0.04 (+0.05%)

FB Facebook
$220.70 /

+4.84 (+2.24%)

F Ford
$6.02 /

+0.11 (+1.86%)

BYND Beyond Meat
$131.52 /

-10.16 (-7.17%)

BBY Best Buy
$86.31 /

+1.58 (+1.86%)

BA Boeing
$194.42 /

+24.51 (+14.43%)

AMZN Amazon.com
$2,682.00 /

-11.16 (-0.41%)

AMC AMC Entertainment
$4.43 /

+0.27 (+6.49%)

ADDYY Adidas
$0.00 /

+ (+0.00%)

BA Boeing
$194.42 /

+24.51 (+14.43%)

06/26/20
Fly Intel: Top five analyst downgrades
06/26/20 RBC Capital
Spirit AeroSystems initiated with an Outperform at RBC Capital
06/26/20 Bernstein
Boeing downgraded to Market Perform from Outperform at Bernstein
06/25/20
Fly Intel: Top five analyst downgrades
SBUX Starbucks
$73.50 /

+1.95 (+2.73%)

06/24/20 JPMorgan
Starbucks price target raised to $78 from $73 at JPMorgan
06/15/20
Fly Intel: Top five analyst initiations
06/15/20 Atlantic Equities
Starbucks initiated with an Overweight at Atlantic Equities
06/11/20
Fly Intel: Top five analyst downgrades
KO Coca-Cola
$44.35 /

+0.77 (+1.77%)

06/17/20 Jefferies
Nestle home-office water business would be a fit for Primo Water, says Jefferies
05/28/20 Credit Suisse
Boston Beer downgraded to Neutral on valuation at Credit Suisse
05/18/20 Guggenheim
Guggenheim raises PepsiCo to 'Best Idea' in Food and Beverage, ups target
05/11/20 Citi
Monster Beverage downgraded to Neutral from Buy at Cit
F Ford
$6.02 /

+0.11 (+1.86%)

06/25/20 Morgan Stanley
Talks with Ford dealer highlight inventory risk, says Morgan Stanley
06/24/20 Morgan Stanley
GM electric vehicle business could be worth $100B, says Morgan Stanley
06/19/20 JPMorgan
Ford price target raised to $7 from $6 at JPMorgan
06/18/20 Jefferies
Jefferies raises price targets for Ford, GM and FCA on balance sheet de-risking
ADDYY Adidas
$0.00 /

+ (+0.00%)

06/26/20 KeyBanc
Gap partnership with Kanye West should help with younger shoppers, says KeyBanc
04/28/20 JPMorgan
Adidas price target lowered to EUR 215 from EUR 220 at JPMorgan
04/28/20 RBC Capital
Adidas price target lowered to EUR 230 from EUR 245 at RBC Capital
04/28/20 Morgan Stanley
Adidas price target lowered to EUR 195 from EUR 200 at Morgan Stanley
FB Facebook
$220.70 /

+4.84 (+2.24%)

06/30/20 Morgan Stanley
Morgan Stanley says buy Facebook amid boycott-driven weakness
06/30/20 Citi
Facebook shares overreacting to pause in ad spending, says Citi
06/29/20 Stifel
Stifel says Facebook sales won't be materially hurt unless ad boycott broadens
06/29/20 JPMorgan
Facebook estimates not at risk from ad boycott, says JPMorgan
MSFT Microsoft
$198.49 /

+2.24 (+1.14%)

06/29/20 JMP Securities
ZoomInfo initiated with a Market Perform at JMP Securities
06/24/20 Bernstein
Potential spinoff would be largely positive for VMware, says Bernstein
06/24/20 Baird
Ping Identity initiated with a Neutral at Baird
06/24/20 Argus
Microsoft price target raised to $235 from $200 at Argus
BBY Best Buy
$86.31 /

+1.58 (+1.86%)

06/23/20 Credit Suisse
Whirlpool price target raised to $103 from $90 at Credit Suisse
06/11/20 Oppenheimer
Roku price target raised to $140 from $135 at Oppenheimer
06/03/20 Stephens
Roku may be seeing pressure from Best Buy TCL TVs, says Stephens
06/03/20 SunTrust
New TVs at Best Buy present 'modest' new competition for Roku, says Suntrust
GILD Gilead
$74.56 /

+0.04 (+0.05%)

06/30/20 Wells Fargo
Remdesivir pricing 'a responsible public health decision,' says Wells Fargo
06/29/20 Piper Sandler
Piper says Gilead sale to HHS should make remdesivir opportunity 'more tangible'
06/29/20 RBC Capital
RBC says HIV, other franchises more critical drivers of Gilead than remdesivir
06/29/20 Piper Sandler
Gilead pricing for Remdesivir 'perfectly reasonable,' says Piper Sandler
ICPT Intercept
$46.66 /

-30.9 (-39.84%)

06/30/20 B. Riley FBR
Intercept selloff yesterday overdone, says B. Riley FBR
06/30/20 Baird
Intercept downgraded to Neutral following "surprise" FDA decision at Baird
06/30/20 BMO Capital
Intercept downgraded to Market Perform from Outperform at BMO Capital
06/30/20 UBS
Intercept downgraded to Neutral from Buy at UBS
HRTX Heron Therapeutics
$14.26 /

-5.555 (-28.04%)

06/29/20 JPMorgan
HTX-011 CRL 'a clear positive' for Pacira, says JPMorgan
06/29/20 Evercore ISI
Heron Therapeutics should be bought on CRL weakness, says Evercore ISI
05/27/20 Guggenheim
Guggenheim starts coverage of four pain treatment makers with two Buys
05/26/20 Guggenheim
Heron Therapeutics initiated with a Buy at Guggenheim
AMZN Amazon.com
$2,682.00 /

-11.16 (-0.41%)

06/30/20 Mizuho
Amazon.com price target raised to $3,100 from $2,550 at Mizuho
06/29/20 Monness Crespi
Amazon.com price target raised to $3,500 from $2,800 at Monness Crespi
06/26/20 Baird
Amazon acquiring Zoox could be 'game-changing,' says Baird
06/26/20 SunTrust
Etsy price target raised to $112 from $88 at SunTrust
AMC AMC Entertainment
$4.43 /

+0.27 (+6.49%)

06/30/20 Imperial Capital
AMC Entertainment price target lowered to $4 from $6 at Imperial Capital
06/29/20 Credit Suisse
Cinemark downgraded to Neutral from Outperform at Credit Suisse
06/29/20 Credit Suisse
AMC Entertainment downgraded to Underperform from Neutral at Credit Suisse
06/17/20 Citi
AMC Entertainment price target raised to $4 from $1 at Citi
IDEX Ideanomics
$2.06 /

+0.61 (+42.07%)

KNSA Kiniksa
$26.00 /

+2.96 (+12.85%)

06/29/20 Goldman Sachs
Kiniksa price target raised to $33 from $29 at Goldman Sachs
06/29/20 Wedbush
Kiniksa price target raised to $38 from $30 at Wedbush
04/01/20
Fly Intel: Top five analyst initiations
04/01/20 BofA
Kiniksa initiated with a Buy at BofA
BYND Beyond Meat
$131.52 /

-10.16 (-7.17%)

06/29/20
Fly Intel: Top five analyst downgrades
06/29/20 Barclays
Barclays double downgrades Beyond Meat to Underweight on restaurant closures
06/29/20 Barclays
Beyond Meat downgraded to Underweight from Overweight at Barclays
06/17/20 Credit Suisse
Beyond Meat price target raised to $142 from $90 at Credit Suisse
SBUX Starbucks
$73.50 /

+1.95 (+2.73%)

MSFT Microsoft
$198.49 /

+2.24 (+1.14%)

KO Coca-Cola
$44.35 /

+0.77 (+1.77%)

KNSA Kiniksa
$26.00 /

+2.96 (+12.85%)

ICPT Intercept
$46.66 /

-30.9 (-39.84%)

HRTX Heron Therapeutics
$14.26 /

-5.555 (-28.04%)

GILD Gilead
$74.56 /

+0.04 (+0.05%)

FB Facebook
$220.70 /

+4.84 (+2.24%)

F Ford
$6.02 /

+0.11 (+1.86%)

BYND Beyond Meat
$131.52 /

-10.16 (-7.17%)

BBY Best Buy
$86.31 /

+1.58 (+1.86%)

BA Boeing
$194.42 /

+24.51 (+14.43%)

AMZN Amazon.com
$2,682.00 /

-11.16 (-0.41%)

AMC AMC Entertainment
$4.43 /

+0.27 (+6.49%)

ADDYY Adidas
$0.00 /

+ (+0.00%)

  • 14
    May
  • 04
    Oct
  • 01
    Aug
SBUX Starbucks
$73.50 /

+1.95 (+2.73%)

MSFT Microsoft
$198.49 /

+2.24 (+1.14%)

KO Coca-Cola
$44.35 /

+0.77 (+1.77%)

IDEX Ideanomics
$2.06 /

+0.61 (+42.07%)

GILD Gilead
$74.56 /

+0.04 (+0.05%)

FB Facebook
$220.70 /

+4.84 (+2.24%)

F Ford
$6.02 /

+0.11 (+1.86%)

BYND Beyond Meat
$131.52 /

-10.16 (-7.17%)

BBY Best Buy
$86.31 /

+1.58 (+1.86%)

BA Boeing
$194.42 /

+24.51 (+14.43%)

AMZN Amazon.com
$2,682.00 /

-11.16 (-0.41%)

AMC AMC Entertainment
$4.43 /

+0.27 (+6.49%)

ADDYY Adidas
$0.00 /

+ (+0.00%)

SBUX Starbucks
$73.50 /

+1.95 (+2.73%)

MSFT Microsoft
$198.49 /

+2.24 (+1.14%)

KO Coca-Cola
$44.35 /

+0.77 (+1.77%)

KNSA Kiniksa
$26.00 /

+2.96 (+12.85%)

IDEX Ideanomics
$2.06 /

+0.61 (+42.07%)

ICPT Intercept
$46.66 /

-30.9 (-39.84%)

HRTX Heron Therapeutics
$14.26 /

-5.555 (-28.04%)

GILD Gilead
$74.56 /

+0.04 (+0.05%)

FB Facebook
$220.70 /

+4.84 (+2.24%)

F Ford
$6.02 /

+0.11 (+1.86%)

BBY Best Buy
$86.31 /

+1.58 (+1.86%)

BA Boeing
$194.42 /

+24.51 (+14.43%)

AMZN Amazon.com
$2,682.00 /

-11.16 (-0.41%)

AMC AMC Entertainment
$4.43 /

+0.27 (+6.49%)

ADDYY Adidas
$0.00 /

+ (+0.00%)

SBUX Starbucks
$73.50 /

+1.95 (+2.73%)

MSFT Microsoft
$198.49 /

+2.24 (+1.14%)

KO Coca-Cola
$44.35 /

+0.77 (+1.77%)

KNSA Kiniksa
$26.00 /

+2.96 (+12.85%)

IDEX Ideanomics
$2.06 /

+0.61 (+42.07%)

GILD Gilead
$74.56 /

+0.04 (+0.05%)

FB Facebook
$220.70 /

+4.84 (+2.24%)

F Ford
$6.02 /

+0.11 (+1.86%)

BYND Beyond Meat
$131.52 /

-10.16 (-7.17%)

BBY Best Buy
$86.31 /

+1.58 (+1.86%)

BA Boeing
$194.42 /

+24.51 (+14.43%)

AMZN Amazon.com
$2,682.00 /

-11.16 (-0.41%)

AMC AMC Entertainment
$4.43 /

+0.27 (+6.49%)

MSFT Microsoft
$198.49 /

+2.24 (+1.14%)

AMZN Amazon.com
$2,682.00 /

-11.16 (-0.41%)

On The Fly
Pacira jumps as competitor Heron receives CRL for pain treatment » 13:12
06/29/20
06/29
13:12
06/29/20
13:12
PCRX

Pacira

$51.95 /

+7.83 (+17.75%)

, HRTX

Heron Therapeutics

$14.62 /

-5.19 (-26.20%)

Shares of Pacira (PCRX)…

Open Full Text

ShowHide Related Items >><<
PCRX Pacira
$51.95 /

+7.83 (+17.75%)

HRTX Heron Therapeutics
$14.62 /

-5.19 (-26.20%)

PCRX Pacira
$51.95 /

+7.83 (+17.75%)

06/30/20 Northland
Pacira price target raised to $54 from $50 at Northland
06/29/20 JPMorgan
HTX-011 CRL 'a clear positive' for Pacira, says JPMorgan
05/27/20 Northland
Pacira downgraded to Market Perform from Outperform at Northland
05/27/20 Guggenheim
Guggenheim starts coverage of four pain treatment makers with two Buys
HRTX Heron Therapeutics
$14.62 /

-5.19 (-26.20%)

06/30/20 Northland
Northland keeps Outperform on Heron Therapeutics after 'minor setback'
06/29/20 Evercore ISI
Heron Therapeutics should be bought on CRL weakness, says Evercore ISI
PCRX Pacira
$51.95 /

+7.83 (+17.75%)

HRTX Heron Therapeutics
$14.62 /

-5.19 (-26.20%)

  • 04
    Oct
PCRX Pacira
$51.95 /

+7.83 (+17.75%)

HRTX Heron Therapeutics
$14.62 /

-5.19 (-26.20%)

On The Fly
Fly Intel: Wall Street's top stories at midday » 12:26
06/29/20
06/29
12:26
06/29/20
12:26
FB

Facebook

$217.43 /

+1.57 (+0.73%)

, SBUX

Starbucks

$72.74 /

+1.19 (+1.66%)

, KO

Coca-Cola

$44.33 /

+0.75 (+1.72%)

, GILD

Gilead

$75.10 /

+0.58 (+0.78%)

, TWTR

Twitter

$29.63 /

+0.58 (+2.00%)

, SNAP

Snap

$22.90 /

-0.16 (-0.69%)

, BA

Boeing

$180.14 /

+10.23 (+6.02%)

, ICPT

Intercept

$47.88 /

-29.68 (-38.27%)

, HRTX

Heron Therapeutics

$14.23 /

-5.585 (-28.19%)

, IDEX

Ideanomics

$2.18 /

+0.73 (+50.34%)

, BYND

Beyond Meat

$128.78 /

-12.9 (-9.11%)

, KNSA

Kiniksa

$27.86 /

+4.82 (+20.92%)

Stocks are rising in a…

Open Full Text

ShowHide Related Items >><<
TWTR Twitter
$29.63 /

+0.58 (+2.00%)

SNAP Snap
$22.90 /

-0.16 (-0.69%)

SBUX Starbucks
$72.74 /

+1.19 (+1.66%)

KO Coca-Cola
$44.33 /

+0.75 (+1.72%)

KNSA Kiniksa
$27.86 /

+4.82 (+20.92%)

IDEX Ideanomics
$2.18 /

+0.73 (+50.34%)

ICPT Intercept
$47.88 /

-29.68 (-38.27%)

HRTX Heron Therapeutics
$14.23 /

-5.585 (-28.19%)

GILD Gilead
$75.10 /

+0.58 (+0.78%)

FB Facebook
$217.43 /

+1.57 (+0.73%)

BYND Beyond Meat
$128.78 /

-12.9 (-9.11%)

BA Boeing
$180.14 /

+10.23 (+6.02%)

FB Facebook
$217.43 /

+1.57 (+0.73%)

06/29/20 JPMorgan
Facebook estimates not at risk from ad boycott, says JPMorgan
06/25/20 Baird
Facebook price target raised to $300 from $240 at Baird
06/24/20 Goldman Sachs
Facebook price target raised to $265 from $250 at Goldman Sachs
06/18/20 Morgan Stanley
Section 230 change likely a multi-year process, says Morgan Stanley
SBUX Starbucks
$72.74 /

+1.19 (+1.66%)

06/24/20 JPMorgan
Starbucks price target raised to $78 from $73 at JPMorgan
06/15/20
Fly Intel: Top five analyst initiations
06/15/20 Atlantic Equities
Starbucks initiated with an Overweight at Atlantic Equities
06/11/20
Fly Intel: Top five analyst downgrades
KO Coca-Cola
$44.33 /

+0.75 (+1.72%)

06/17/20 Jefferies
Nestle home-office water business would be a fit for Primo Water, says Jefferies
05/28/20 Credit Suisse
Boston Beer downgraded to Neutral on valuation at Credit Suisse
05/18/20 Guggenheim
Guggenheim raises PepsiCo to 'Best Idea' in Food and Beverage, ups target
05/11/20 Citi
Monster Beverage downgraded to Neutral from Buy at Cit
GILD Gilead
$75.10 /

+0.58 (+0.78%)

06/29/20 RBC Capital
RBC says HIV, other franchises more critical drivers of Gilead than remdesivir
06/29/20 Piper Sandler
Gilead pricing for Remdesivir 'perfectly reasonable,' says Piper Sandler
06/29/20 B. Riley FBR
Durect should be bought on weakness from Gilead termination, says B. Riley FBR
06/29/20 H.C. Wainwright
Durect thesis unchanged after Gilead termination, says H.C. Wainwright
TWTR Twitter
$29.63 /

+0.58 (+2.00%)

06/22/20 Citi
Twitter price target raised to $36 from $30 at Citi
06/16/20 JPMorgan
JPMorgan continues to prefer Facebook, Snap in online advertising
SNAP Snap
$22.90 /

-0.16 (-0.69%)

06/26/20 Wells Fargo
Snap price target raised to $28 from $20 at Wells Fargo
06/25/20 Citi
Citi recommends pair trade of buying Omnicom, selling Snap
06/24/20 Wedbush
Snap price target raised to $16 from $12.25 at Wedbush
BA Boeing
$180.14 /

+10.23 (+6.02%)

06/26/20
Fly Intel: Top five analyst downgrades
06/26/20 RBC Capital
Spirit AeroSystems initiated with an Outperform at RBC Capital
06/26/20 Bernstein
Boeing downgraded to Market Perform from Outperform at Bernstein
06/25/20
Fly Intel: Top five analyst downgrades
ICPT Intercept
$47.88 /

-29.68 (-38.27%)

06/29/20 RBC Capital
RBC downgrades Intercept on 'fundamental questioning' of drug
06/29/20 RBC Capital
Intercept downgraded to Sector Perform from Outperform at RBC Capital
06/29/20 Canaccord
Intercept downgraded to Hold from Buy at Canaccord after receiving FDA CRL
06/29/20 Canaccord
Intercept downgraded to Hold from Buy at Canaccord
HRTX Heron Therapeutics
$14.23 /

-5.585 (-28.19%)

06/29/20 JPMorgan
HTX-011 CRL 'a clear positive' for Pacira, says JPMorgan
06/29/20 Evercore ISI
Heron Therapeutics should be bought on CRL weakness, says Evercore ISI
05/27/20 Guggenheim
Guggenheim starts coverage of four pain treatment makers with two Buys
05/26/20 Guggenheim
Heron Therapeutics initiated with a Buy at Guggenheim
IDEX Ideanomics
$2.18 /

+0.73 (+50.34%)

BYND Beyond Meat
$128.78 /

-12.9 (-9.11%)

06/29/20
Fly Intel: Top five analyst downgrades
06/29/20 Barclays
Barclays double downgrades Beyond Meat to Underweight on restaurant closures
06/29/20 Barclays
Beyond Meat downgraded to Underweight from Overweight at Barclays
06/17/20 Credit Suisse
Beyond Meat price target raised to $142 from $90 at Credit Suisse
KNSA Kiniksa
$27.86 /

+4.82 (+20.92%)

06/29/20 Goldman Sachs
Kiniksa price target raised to $33 from $29 at Goldman Sachs
06/29/20 Wedbush
Kiniksa price target raised to $38 from $30 at Wedbush
04/01/20
Fly Intel: Top five analyst initiations
04/01/20 BofA
Kiniksa initiated with a Buy at BofA
TWTR Twitter
$29.63 /

+0.58 (+2.00%)

SNAP Snap
$22.90 /

-0.16 (-0.69%)

SBUX Starbucks
$72.74 /

+1.19 (+1.66%)

KO Coca-Cola
$44.33 /

+0.75 (+1.72%)

KNSA Kiniksa
$27.86 /

+4.82 (+20.92%)

ICPT Intercept
$47.88 /

-29.68 (-38.27%)

HRTX Heron Therapeutics
$14.23 /

-5.585 (-28.19%)

GILD Gilead
$75.10 /

+0.58 (+0.78%)

FB Facebook
$217.43 /

+1.57 (+0.73%)

BYND Beyond Meat
$128.78 /

-12.9 (-9.11%)

BA Boeing
$180.14 /

+10.23 (+6.02%)

  • 14
    May
  • 04
    Oct
  • 01
    Aug
TWTR Twitter
$29.63 /

+0.58 (+2.00%)

SNAP Snap
$22.90 /

-0.16 (-0.69%)

SBUX Starbucks
$72.74 /

+1.19 (+1.66%)

KO Coca-Cola
$44.33 /

+0.75 (+1.72%)

IDEX Ideanomics
$2.18 /

+0.73 (+50.34%)

GILD Gilead
$75.10 /

+0.58 (+0.78%)

FB Facebook
$217.43 /

+1.57 (+0.73%)

BYND Beyond Meat
$128.78 /

-12.9 (-9.11%)

BA Boeing
$180.14 /

+10.23 (+6.02%)

SNAP Snap
$22.90 /

-0.16 (-0.69%)

SBUX Starbucks
$72.74 /

+1.19 (+1.66%)

KO Coca-Cola
$44.33 /

+0.75 (+1.72%)

KNSA Kiniksa
$27.86 /

+4.82 (+20.92%)

IDEX Ideanomics
$2.18 /

+0.73 (+50.34%)

ICPT Intercept
$47.88 /

-29.68 (-38.27%)

GILD Gilead
$75.10 /

+0.58 (+0.78%)

FB Facebook
$217.43 /

+1.57 (+0.73%)

BYND Beyond Meat
$128.78 /

-12.9 (-9.11%)

BA Boeing
$180.14 /

+10.23 (+6.02%)

TWTR Twitter
$29.63 /

+0.58 (+2.00%)

SNAP Snap
$22.90 /

-0.16 (-0.69%)

SBUX Starbucks
$72.74 /

+1.19 (+1.66%)

KO Coca-Cola
$44.33 /

+0.75 (+1.72%)

KNSA Kiniksa
$27.86 /

+4.82 (+20.92%)

IDEX Ideanomics
$2.18 /

+0.73 (+50.34%)

GILD Gilead
$75.10 /

+0.58 (+0.78%)

FB Facebook
$217.43 /

+1.57 (+0.73%)

BYND Beyond Meat
$128.78 /

-12.9 (-9.11%)

BA Boeing
$180.14 /

+10.23 (+6.02%)

Recommendations
HTX-011 CRL 'a clear positive' for Pacira, says JPMorgan » 11:35
06/29/20
06/29
11:35
06/29/20
11:35
PCRX

Pacira

$51.85 /

+7.73 (+17.52%)

, HRTX

Heron Therapeutics

$14.77 /

-5.04 (-25.44%)

JPMorgan analyst Chris…

JPMorgan analyst Chris Schott notes that This morning, Heron Therapeutics (HRTX) announced that it again received a CRL for HTX-011, a potential Pacira's (PCRX) Exparel competitor, with the FDA requiring additional non-clinical information on the product. The main issues identified in the review included "confirming exposure of excipients in preclinical reproductive toxicology studies" and "changing the manufacturing release specification of the allowable level of an impurity," he points out, adding that Heron will work with the FDA to address these points. Overall, Schott sees the news as a clear positive for Pacira, enabling the Exparel to further entrench itself ahead of any competition and raising questions around HTX-011's profile and time to approve. More broadly on the Pacira story, while COVID-19 will obviously pressure near-term results, the analyst sees several factors, including increased use among anesthesiologists and further penetration in outpatient, supporting strong Exparel uptake in 2021-plus. He has a Neutral rating on Pacira's shares.

ShowHide Related Items >><<
PCRX Pacira
$51.85 /

+7.73 (+17.52%)

HRTX Heron Therapeutics
$14.77 /

-5.04 (-25.44%)

PCRX Pacira
$51.85 /

+7.73 (+17.52%)

05/27/20 Northland
Pacira downgraded to Market Perform from Outperform at Northland
05/27/20 Guggenheim
Guggenheim starts coverage of four pain treatment makers with two Buys
05/26/20 Guggenheim
Pacira initiated with a Neutral at Guggenheim
04/07/20
Fly Intel: Top five analyst initiations
HRTX Heron Therapeutics
$14.77 /

-5.04 (-25.44%)

06/29/20 Evercore ISI
Heron Therapeutics should be bought on CRL weakness, says Evercore ISI
05/26/20 Guggenheim
Heron Therapeutics initiated with a Buy at Guggenheim
02/24/20 H.C. Wainwright
Pacira price target raised to $63 from $60 at H.C. Wainwright
PCRX Pacira
$51.85 /

+7.73 (+17.52%)

HRTX Heron Therapeutics
$14.77 /

-5.04 (-25.44%)

  • 04
    Oct
Recommendations
Heron Therapeutics should be bought on CRL weakness, says Evercore ISI » 10:21
06/29/20
06/29
10:21
06/29/20
10:21
HRTX

Heron Therapeutics

$14.15 /

-5.66 (-28.57%)

Evercore ISI analyst…

Evercore ISI analyst Joshua Schimmer said he would be a buyer of Heron Therapeutics amid the weakness following the receipt of a CRL from the FDA as he believes the issues "read trivial." Heron will request a Type A FDA meeting within 30 days, can hopefully quickly make a resubmission with a two month review and possibly still get approval by year-end, the analyst said. He has an Outperform rating and $70 price target on Heron shares, which are down $5.68, or 29%, to $14.18 in morning trading.

ShowHide Related Items >><<
HRTX Heron Therapeutics
$14.15 /

-5.66 (-28.57%)

HRTX Heron Therapeutics
$14.15 /

-5.66 (-28.57%)

05/27/20 Guggenheim
Guggenheim starts coverage of four pain treatment makers with two Buys
05/26/20 Guggenheim
Heron Therapeutics initiated with a Buy at Guggenheim
02/24/20 H.C. Wainwright
Pacira price target raised to $63 from $60 at H.C. Wainwright
02/20/20 Piper Sandler
Pacira price target raised to $60 from $54 at Piper Sandler
HRTX Heron Therapeutics
$14.15 /

-5.66 (-28.57%)

  • 04
    Oct
Hot Stocks
Heron Therapeutics trading resumes  09:10
06/29/20
06/29
09:10
06/29/20
09:10
HRTX

Heron Therapeutics

$19.81 /

-0.72 (-3.51%)

 
ShowHide Related Items >><<
HRTX Heron Therapeutics
$19.81 /

-0.72 (-3.51%)

HRTX Heron Therapeutics
$19.81 /

-0.72 (-3.51%)

05/27/20 Guggenheim
Guggenheim starts coverage of four pain treatment makers with two Buys
05/26/20 Guggenheim
Heron Therapeutics initiated with a Buy at Guggenheim
02/24/20 H.C. Wainwright
Pacira price target raised to $63 from $60 at H.C. Wainwright
02/20/20 Piper Sandler
Pacira price target raised to $60 from $54 at Piper Sandler
HRTX Heron Therapeutics
$19.81 /

-0.72 (-3.51%)

  • 04
    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.